Taysha Gene Therapies, Inc. TSHA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities?
- Taysha Gene Therapies, Inc. (TSHA) reported accrued expenses and other liabilities of $15.53M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities increased by 44.4% year-over-year, from $10.76M to $15.53M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s accrued expenses and other liabilities has grown at a 31.6% compound annual growth rate (CAGR), from $5.14M to $20.28M.